Monitoring Anti-Dementia Drugs by Serum Levels

PHASE4CompletedINTERVENTIONAL
Enrollment

132

Participants

Timeline

Start Date

February 4, 2020

Primary Completion Date

February 16, 2023

Study Completion Date

February 16, 2023

Conditions
DementiaDementia With Lewy BodiesDementia in Parkinsons DiseaseDementia AlzheimersAlzheimer Disease
Interventions
DRUG

Donepezil

Adjustment of treatment with donepezil according to serum level.

DRUG

Memantine

Adjustment of treatment with memantine according to serum level.

DIAGNOSTIC_TEST

Measurement of serum level of anti-dementia drug

"Participants allocated to the intervention arm are requested to inform the sponsor of any side effects up to 2 months after prescription of the anti-dementia drug. If so, they will have their treatment adjusted according to the serum level. Participants in the intervention group not experiencing side effects will have their treatment adjusted after 6 months based upon serum levels of the drug in question.~Participants allocated to the standard of care arm follow the usual routines of the dementia clinic but are requested to have the serum level of the prescribed drug and CYP2D6-genotype measured after 12 month."

Trial Locations (1)

4000

Regionalt Videnscenter for Demens, Roskilde

All Listed Sponsors
collaborator

Filadelfia Epilepsy Hospital

OTHER

lead

Zealand University Hospital

OTHER

NCT04117178 - Monitoring Anti-Dementia Drugs by Serum Levels | Biotech Hunter | Biotech Hunter